RP Management LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:RP Management LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013291
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
RP Management LLC (RP Management) is a life sciences financing company which offers biopharmaceutical products. Its products portfolio includes rituxan, atripla, thalomid, myozyme, lexiscan, januvia, onglyza, lyrica, prezista, letairis, rotateq, cubicin, savella, neupogen, and others. The company also provides remicade, humira, galvus, nesina, tradjenta, viviant, cimzia, mircera, tecfidera, imbruvica, Xtandi and priligy. RP Management has interests in approved and late stage development bio-pharmaceutical products. It offers its approved products in the therapeutic areas of rheumatoid arthritis (RA), Crohn’s disease, diabetes, chronic kidney disease, HIV/AIDS and others. The company operates through research institutions, inventors, biotechnology and pharmaceutical companies. RP Management is headquartered in New York, the US.

RP Management LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
RP Management LLC, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 10
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 12
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 14
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 16
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 17
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 18
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 19
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 21
Prosidion Completes Sale Of Dipeptidyl Peptidase IV Patent Estate And Associated Royalty Interest To Royalty Pharma 22
Royalty Pharma Acquires Royalties Of Lexiscan And Cubicin 24
Venture Financing 25
Avillion Secures Funds from Royalty Pharma 25
Private Equity 26
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 26
RP Management LLC – Key Competitors 27
RP Management LLC – Key Employees 28
RP Management LLC – Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
RP Management LLC, Pharmaceuticals & Healthcare, Key Facts 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
RP Management LLC, Deals By Therapy Area, 2011 to YTD 2017 8
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 10
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 12
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 14
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 16
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 17
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 18
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 19
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 21
Prosidion Completes Sale Of Dipeptidyl Peptidase IV Patent Estate And Associated Royalty Interest To Royalty Pharma 22
Royalty Pharma Acquires Royalties Of Lexiscan And Cubicin 24
Avillion Secures Funds from Royalty Pharma 25
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 26
RP Management LLC, Key Competitors 27
RP Management LLC, Key Employees 28

★海外企業調査レポート[RP Management LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Atria Plc:戦略・SWOT・企業財務分析
    Atria Plc - Strategy, SWOT and Corporate Finance Report Summary Atria Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Oncolytics Biotech Inc (ONC)-医療機器分野:企業M&A・提携分析
    Summary Oncolytics Biotech Inc (Oncolytics) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product, Reolysin, a formulation of the human reovirus, is at Phase II clinical trials indi …
  • Reliance Capital Ltd:企業の戦略・SWOT・財務分析
    Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report Summary Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Renewable Energy Group, Inc.:企業の戦略・SWOT・財務分析
    Renewable Energy Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Renewable Energy Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • RegenxBio Inc (RGNX):製薬・医療:M&Aディール及び事業提携情報
    Summary RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC is a provider of therapeutics for various diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AA …
  • Lenovo Group Ltd (992):企業の財務・戦略的SWOT分析
    Lenovo Group Ltd (992) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Lee & Man Paper Manufacturing Ltd:企業の戦略・SWOT・財務情報
    Lee & Man Paper Manufacturing Ltd - Strategy, SWOT and Corporate Finance Report Summary Lee & Man Paper Manufacturing Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Tulmar Safety Systems Inc.:企業の戦略・SWOT・財務情報
    Tulmar Safety Systems Inc. - Strategy, SWOT and Corporate Finance Report Summary Tulmar Safety Systems Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Progress Software Corp (PRGS):企業の財務・戦略的SWOT分析
    Progress Software Corp (PRGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Terme Dobrna D.D.
    Terme Dobrna D.D. - Strategy, SWOT and Corporate Finance Report Summary Terme Dobrna D.D. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Investec Private Bank (South Africa):企業の戦略・SWOT・財務情報
    Investec Private Bank (South Africa) - Strategy, SWOT and Corporate Finance Report Summary Investec Private Bank (South Africa) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Thai Airways International Public Co Ltd:企業の戦略・SWOT・財務情報
    Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • MedNet Solutions Inc-医療機器分野:企業M&A・提携分析
    Summary MedNet Solutions Inc (MedNet Solutions) is a healthcare technology company which provides eClinical and electronic data capture software solutions. The company developed iMedNet, an eClinical technology platform which provides non – technical clinical research for clinical trials or studies. …
  • Uniper SE (UN01):電力:M&Aディール及び事業提携情報
    Summary Uniper SE (Uniper) is an energy utility service provider. The company generates electricity primarily through coal, hydro, oil and gas sources. It offers commodity trading services for power, natural gas, emission certificates, liquefied natural gas, coal and freight. Uniper also provides th …
  • Veracyte Inc (VCYT):医療機器:M&Aディール及び事業提携情報
    Summary Veracyte Inc (Veracyte) is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The company’s pipeline products include Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary afirma gene expression classifier. It also …
  • McAfee, Inc.:企業の戦略的SWOT分析
    McAfee, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Coherent Inc (COHR):企業の財務・戦略的SWOT分析
    Coherent Inc (COHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • People’S Bank:企業の戦略・SWOT・財務分析
    People'S Bank - Strategy, SWOT and Corporate Finance Report Summary People'S Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Slater and Gordon Limited:企業の戦略・SWOT・財務情報
    Slater and Gordon Limited - Strategy, SWOT and Corporate Finance Report Summary Slater and Gordon Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Natco Pharma Ltd (NATCOPHARM):製薬・医療:M&Aディール及び事業提携情報
    Summary Natco Pharma Ltd (Natco Pharma) focuses on the research, development, manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage forms in capsule, injection and tablet. Its products are indicated to treat multiple sclerosis, i …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆